Tradestie Institutional Equity Comparison Engine

PTN vs OBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

OBIO Overall Edge

OBIO Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) driven by superior Momentum & Technical, Options & Structure while PTN counters with relative strength in Valuation, Growth & Margin. Fundamentally, PTN trades at 42.9x Forward P/E with -65.7% operating margin (-80.1% YoY revenue) versus OBIO at N/M Forward P/E and -195.4% operating margin (-89.4% YoY). In options structure, PTN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against OBIO sits in BREAKOUT (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner PTN
PTN 42.9x vs OBIO N/M Fwd P/E
Growth & Margin Winner PTN
Op Margin -65.7% vs -195.4% ยท YoY -80.1% vs -89.4%
Momentum & Technical Winner OBIO
1Y -43.3% vs +70.3% ยท 52W Pos 6% vs 92%
Options & Structure Winner OBIO
UNCLASSIFIED (N/A IV) vs BREAKOUT (<1st %ile IV)
PTN US Equity
Palatin Technologies, Inc.
Pharmaceutical Preparations
$6.12
-1.69% 1D
Market Cap $11.1M
1M Return +1.74%
1Y Return -43.29%
Forward P/E 42.9x
Unified AI Score
31.5 / 100 SELL
Tech 15.0 Fund 30.0 Flow 50.0 Mom 40.0
OBIO NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.12
-1.79% 1D
Market Cap $570.6M
1M Return +30.64%
1Y Return +70.33%
Forward P/E N/M
Unified AI Score
37.5 / 100 SELL
Tech 15.0 Fund 36.0 Flow 55.0 Mom 44.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: PTN -43.29% OBIO +70.33% Spread: +113.62 pp (OBIO Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period PTN Revenue OBIO Revenue PTN Op. Margin OBIO Op. Margin Margin Edge
FY2018 $70M N/A 38.6% N/A PTN
FY2019 $60M N/A 59.3% N/A PTN
FY2020 $0M N/A -20007.6% N/A PTN
FY2022 $0M $0M -2491.6% -924.3% OBIO
FY2023 $0M $0M -668.7% -1866.2% PTN
FY2024 $0M $0M -501.0% -2437.5% PTN
FY2025 N/A $30M N/A -154.7% OBIO
FY2026 $10M N/A -65.7% N/A PTN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: PTN (5) vs OBIO (5)
Institutional Metric PTN OBIO Criterion Row Winner
Market Capitalization Scale $11.1M $570.6M Larger Scale OBIO
Trailing P/E Ratio Valuation 42.9x N/M Lower Multiple PTN
Forward P/E Ratio Valuation 42.9x N/M Lower Multiple PTN
Revenue Growth (YoY) Growth -80.1% -89.4% Higher Growth PTN
Operating Margin (TTM) Profitability -65.7% -195.4% Higher Margin PTN
Net Profit Margin Profitability -63.5% -182.5% Higher Margin PTN
Return on Equity (ROE) Capital Efficiency -877.5% -182.3% Higher ROE OBIO
52-Week Range Position Momentum 6% ($5โ€“$31) 92% ($3โ€“$7) Stronger Trend OBIO
Beta / 30D Volatility Risk Regime 0.87ฮฒ ยท 106% Vol 1.15ฮฒ ยท 82% Vol Lower Realized Risk OBIO
Unified Institutional Score Composite Signal 31.5 / 100 (SELL) 37.5 / 100 (SELL) Higher Composite OBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full PTN vs OBIO Buy Guide
PTN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live PTN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
OBIO BREAKOUT
32d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live OBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither PTN nor OBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.